🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Grateful to have collaborated on this! Talha Badar Alexander Coltoff, MD #leusm #ALL #MRD library.ehaweb.org/eha/2024/eha20…

Thanks The Lancet Haematology for allowing me to reflect on my job, and thanks #SEVERANCE for the inspiration. thelancet.com/journals/lanha…

Landmark Paper: the study published in 1998 by Bloomfield et al. established the standard for consolidation therapy in acute myeloid leukemia patients with core binding factor abnormalities. haematologica.org/article/view/1…

#EHA2024 #EHA24 #poster_session #TP53m #MPN #mpnsm Genomic landscape, impact allelic burden, time to progression from CP-AP/BP in TP53m MPN—> AML TP53m with VAF>40 had poorer outcome. No significant impact of type of induction on outcome. Special thanks to

onlinelibrary.wiley.com/doi/10.1002/aj… ARES - ET randomized 1:1 asa qd vs bid - Decrease in TXB2 with bid - no difference in thrombosis (to be expected with 20 mo f/u) - Some symptoms better w/bid, but open-label and all pts on asa at start (role for step-wise asa escalation for sx control?)

onlinelibrary.wiley.com/doi/10.1002/aj… - 84 AML pts stopped VEN (55%) or HMA+VEN (45%) - Median f/u 23 mos, only pts off tx for 3+ mos included - mOS 44 mos, mTFS 16 mos (whole cohort) - mOS 19 mos, mTFS 10 mos (R/R) - NPM1 MRD- (only 7 pts) 2-year OS 100% - Very selected pop, but encouraging

onlinelibrary.wiley.com/doi/10.1002/aj… More data regarding clinical and prognostic utility of D14 marrows. Most interesting to me was 63% of pts with RD at D14 had CR at count recovery. Personally, I almost never re-induce on D14 for good-risk and even hesitate for most intermediate-risk.

In the latest episode of “PV Pod: Stories from the Marrow,” Dr. Douglas Tremblay from Mount Sinai School of Medicine discusses #PolycythemiaVera (PV) progression and the challenges in predicting and preventing this #RareDisease. Listen to PV Pod here: pod.link/1683012869

👉👉👉Delighted to invite you to join us #MPNCarolinas24 ➡️ Aug 23-35,2024 #Asheville NC for our first annual MPN Workshop of The Carolinas 2024 ➡️ a re-boot of our #TXMPNWorkshop series! 🙌 Chairs: Ruben A. Mesa, MD & Naveen Pemmaraju, MD | #MPNSM | VJHemOnc 👏 southpiedmontahec.org/event/71827

So grateful for our amazing #MPNworkshopNC co-chairs for helping us put together an incredible meeting in amazing #AshevilleNC Naveen Pemmaraju, MD Lindsay Rein Brandi Reeves Alexander Coltoff, MD #RupaliBhave #MikeGrunwald Levine Cancer Wake Forest Baptist - Comprehensive Cancer Center Duke Cancer UNC Lineberger MUSC Hollings Cancer Center

When will the candidates address the real issues?

Grateful to have presented our experience with Pacritinib and Momelotinib after Ruxolitinib failure in patients with Myelofibrosis Society of Hematologic Oncology (SOHO) #SOHO2024 We observed trends toward ⬆️ Hgb, ⬆️ PLT, and ⬇️ in transfusion dependency within 3 months of use #mpnsm #HemOnc

LGM

#LFGM

Thrilled to be presenting at ASH #ASH2024, our abstract on extended vs. standard duration HMA+Ven in ND-AML! Always grateful to be working with Dr. Alexander Coltoff, MD and our collaborators from Tampa General Hospital University of South Florida and Mount Sinai Health System ash.confex.com/ash/2024/webpr…

Be sure to check out the great work led by Georgio Medawar, MD tonight on extended vs standard HMA dosing with VEN for ND AML! ash.confex.com/ash/2024/webpr…

Review of fedratinib with John Mascarenhas. First Downey Jr, then McConaughey - is fedratinib going to have a career renaissance as well? ashpublications.org/bloodadvances/…

🚨 Latest paper from #COMMAND_consortium, reporting heterogeneity in clinical outcomes in #TP53m MPN, one of largest cohort of TP53m MPN: 1. Multihit TP53 had inferior outcome in chronic phase MPN, not so in MPN-AP or BP. Similar to our reports in HR-MDS/AML. 2. MH TP53 commonly